Sentinel lymph node biopsy using single-agent mapping tracer (blue dye) after neoadjuvant chemotherapy in a Brazilian cohort of breast cancer patients. Real world evidence
ABSTRACT Purpose To reduce false-negative rates (FNR) in sentinel lymph node biopsy (SLNB) of clinically positive (cN+) axilla in patients undergoing neoadjuvant chemotherapy (NAC). The removal of three or more lymph nodes with dual-tracer mapping including a radioisotope was used. However, in the...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sociedade Brasileira para o Desenvolvimento da Pesquisa em Cirurgia
2021-07-01
|
| Series: | Acta Cirúrgica Brasileira |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-86502021000600800&tlng=en |
| _version_ | 1819106234339426304 |
|---|---|
| author | Heloisa Magda Resende Martina Lichtenfels Igor Camargo Soares Angélica Araújo Cortines Laxe Renó Ana Paula Cunha Pedro Gustavo Falcão Carolina Soares Pimentel Pieroni Biazi Ricieri de Assis Paola Cardoso Pedro Henrique Adário Marassi Rafael dos Santos Reis |
| author_facet | Heloisa Magda Resende Martina Lichtenfels Igor Camargo Soares Angélica Araújo Cortines Laxe Renó Ana Paula Cunha Pedro Gustavo Falcão Carolina Soares Pimentel Pieroni Biazi Ricieri de Assis Paola Cardoso Pedro Henrique Adário Marassi Rafael dos Santos Reis |
| author_sort | Heloisa Magda Resende |
| collection | DOAJ |
| description | ABSTRACT Purpose To reduce false-negative rates (FNR) in sentinel lymph node biopsy (SLNB) of clinically positive (cN+) axilla in patients undergoing neoadjuvant chemotherapy (NAC). The removal of three or more lymph nodes with dual-tracer mapping including a radioisotope was used. However, in the Brazilian Unified Health System, the radioisotope tracer is not feasible in some hospitals. We conducted a cross-sectional study to evaluate the detection rate of sentinel lymph node (SLN) in patients who converted from cN+ to ycN0 after NAC using blue dye as a single-agent mapping tracer. Methods During the period of March 2018 to September 2019, 34 patients who underwent NAC with cN+ who converted to ycN0 were enrolled in the study. The SLNB was performed using blue dye as a single-agent mapping followed by axillary lymph node dissection (ALND). Results The detection rate of sentinel lymph node was of 85.3%, being SLNB not possible for five patients (14.7%), due to fibrosis. The mean number of removed SLN was 2.5. Conclusions The use of blue dye as a single-agent mapping tracer demonstrated an acceptable detection rate of 85.3%. Although the FNR was possible to be determined, the small sample size might overestimate this rate. The removal of three or more lymph nodes with single-agent mapping tracer might be indicated for breast cancer patients who converted to ycN0 after NAC in the Brazilian health public services, in which radioisotope tracer is not suitable. |
| first_indexed | 2024-12-22T02:34:54Z |
| format | Article |
| id | doaj.art-b95b90f9054e4926acff605c74172b96 |
| institution | Directory Open Access Journal |
| issn | 0102-8650 |
| language | English |
| last_indexed | 2024-12-22T02:34:54Z |
| publishDate | 2021-07-01 |
| publisher | Sociedade Brasileira para o Desenvolvimento da Pesquisa em Cirurgia |
| record_format | Article |
| series | Acta Cirúrgica Brasileira |
| spelling | doaj.art-b95b90f9054e4926acff605c74172b962022-12-21T18:41:47ZengSociedade Brasileira para o Desenvolvimento da Pesquisa em CirurgiaActa Cirúrgica Brasileira0102-86502021-07-0136610.1590/acb360608Sentinel lymph node biopsy using single-agent mapping tracer (blue dye) after neoadjuvant chemotherapy in a Brazilian cohort of breast cancer patients. Real world evidenceHeloisa Magda Resendehttps://orcid.org/0000-0003-4692-3743Martina Lichtenfelshttps://orcid.org/0000-0003-4783-4646Igor Camargo Soareshttps://orcid.org/0000-0001-8219-5988Angélica Araújo Cortines Laxe Renóhttps://orcid.org/0000-0002-6799-7605Ana Paula Cunhahttps://orcid.org/0000-0002-3871-7264Pedro Gustavo Falcãohttps://orcid.org/0000-0003-4394-3271Carolina Soares Pimentel Pieronihttps://orcid.org/0000-0001-7645-7128Biazi Ricieri de Assishttps://orcid.org/0000-0002-2727-5472Paola Cardosohttps://orcid.org/0000-0001-8722-9104Pedro Henrique Adário Marassihttps://orcid.org/0000-0001-6405-5068Rafael dos Santos Reishttps://orcid.org/0000-0002-4031-3349ABSTRACT Purpose To reduce false-negative rates (FNR) in sentinel lymph node biopsy (SLNB) of clinically positive (cN+) axilla in patients undergoing neoadjuvant chemotherapy (NAC). The removal of three or more lymph nodes with dual-tracer mapping including a radioisotope was used. However, in the Brazilian Unified Health System, the radioisotope tracer is not feasible in some hospitals. We conducted a cross-sectional study to evaluate the detection rate of sentinel lymph node (SLN) in patients who converted from cN+ to ycN0 after NAC using blue dye as a single-agent mapping tracer. Methods During the period of March 2018 to September 2019, 34 patients who underwent NAC with cN+ who converted to ycN0 were enrolled in the study. The SLNB was performed using blue dye as a single-agent mapping followed by axillary lymph node dissection (ALND). Results The detection rate of sentinel lymph node was of 85.3%, being SLNB not possible for five patients (14.7%), due to fibrosis. The mean number of removed SLN was 2.5. Conclusions The use of blue dye as a single-agent mapping tracer demonstrated an acceptable detection rate of 85.3%. Although the FNR was possible to be determined, the small sample size might overestimate this rate. The removal of three or more lymph nodes with single-agent mapping tracer might be indicated for breast cancer patients who converted to ycN0 after NAC in the Brazilian health public services, in which radioisotope tracer is not suitable.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-86502021000600800&tlng=enSentinel Lymph Node BiopsyLymph Node ExcisionNeoadjuvant TherapyBreast Neoplasms |
| spellingShingle | Heloisa Magda Resende Martina Lichtenfels Igor Camargo Soares Angélica Araújo Cortines Laxe Renó Ana Paula Cunha Pedro Gustavo Falcão Carolina Soares Pimentel Pieroni Biazi Ricieri de Assis Paola Cardoso Pedro Henrique Adário Marassi Rafael dos Santos Reis Sentinel lymph node biopsy using single-agent mapping tracer (blue dye) after neoadjuvant chemotherapy in a Brazilian cohort of breast cancer patients. Real world evidence Acta Cirúrgica Brasileira Sentinel Lymph Node Biopsy Lymph Node Excision Neoadjuvant Therapy Breast Neoplasms |
| title | Sentinel lymph node biopsy using single-agent mapping tracer (blue dye) after neoadjuvant chemotherapy in a Brazilian cohort of breast cancer patients. Real world evidence |
| title_full | Sentinel lymph node biopsy using single-agent mapping tracer (blue dye) after neoadjuvant chemotherapy in a Brazilian cohort of breast cancer patients. Real world evidence |
| title_fullStr | Sentinel lymph node biopsy using single-agent mapping tracer (blue dye) after neoadjuvant chemotherapy in a Brazilian cohort of breast cancer patients. Real world evidence |
| title_full_unstemmed | Sentinel lymph node biopsy using single-agent mapping tracer (blue dye) after neoadjuvant chemotherapy in a Brazilian cohort of breast cancer patients. Real world evidence |
| title_short | Sentinel lymph node biopsy using single-agent mapping tracer (blue dye) after neoadjuvant chemotherapy in a Brazilian cohort of breast cancer patients. Real world evidence |
| title_sort | sentinel lymph node biopsy using single agent mapping tracer blue dye after neoadjuvant chemotherapy in a brazilian cohort of breast cancer patients real world evidence |
| topic | Sentinel Lymph Node Biopsy Lymph Node Excision Neoadjuvant Therapy Breast Neoplasms |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-86502021000600800&tlng=en |
| work_keys_str_mv | AT heloisamagdaresende sentinellymphnodebiopsyusingsingleagentmappingtracerbluedyeafterneoadjuvantchemotherapyinabraziliancohortofbreastcancerpatientsrealworldevidence AT martinalichtenfels sentinellymphnodebiopsyusingsingleagentmappingtracerbluedyeafterneoadjuvantchemotherapyinabraziliancohortofbreastcancerpatientsrealworldevidence AT igorcamargosoares sentinellymphnodebiopsyusingsingleagentmappingtracerbluedyeafterneoadjuvantchemotherapyinabraziliancohortofbreastcancerpatientsrealworldevidence AT angelicaaraujocortineslaxereno sentinellymphnodebiopsyusingsingleagentmappingtracerbluedyeafterneoadjuvantchemotherapyinabraziliancohortofbreastcancerpatientsrealworldevidence AT anapaulacunha sentinellymphnodebiopsyusingsingleagentmappingtracerbluedyeafterneoadjuvantchemotherapyinabraziliancohortofbreastcancerpatientsrealworldevidence AT pedrogustavofalcao sentinellymphnodebiopsyusingsingleagentmappingtracerbluedyeafterneoadjuvantchemotherapyinabraziliancohortofbreastcancerpatientsrealworldevidence AT carolinasoarespimentelpieroni sentinellymphnodebiopsyusingsingleagentmappingtracerbluedyeafterneoadjuvantchemotherapyinabraziliancohortofbreastcancerpatientsrealworldevidence AT biaziricierideassis sentinellymphnodebiopsyusingsingleagentmappingtracerbluedyeafterneoadjuvantchemotherapyinabraziliancohortofbreastcancerpatientsrealworldevidence AT paolacardoso sentinellymphnodebiopsyusingsingleagentmappingtracerbluedyeafterneoadjuvantchemotherapyinabraziliancohortofbreastcancerpatientsrealworldevidence AT pedrohenriqueadariomarassi sentinellymphnodebiopsyusingsingleagentmappingtracerbluedyeafterneoadjuvantchemotherapyinabraziliancohortofbreastcancerpatientsrealworldevidence AT rafaeldossantosreis sentinellymphnodebiopsyusingsingleagentmappingtracerbluedyeafterneoadjuvantchemotherapyinabraziliancohortofbreastcancerpatientsrealworldevidence |